blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3036007

EP3036007 - CANCER TREATMENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.08.2020
Database last updated on 25.09.2024
FormerThe patent has been granted
Status updated on  06.09.2019
FormerGrant of patent is intended
Status updated on  18.06.2019
FormerExamination is in progress
Status updated on  14.12.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue NW
Suite 300
Washington, DC 20037 / US
[2016/26]
Inventor(s)01 / POLYMEROPOULOS, Mihael, H.
10627 Rivers Bend Lane
Potomac, MD 20854 / US
02 / LICAMELE, Louis, William
2270 Dunster Lane
Potomac, MD 20854 / US
03 / LAVEDAN, Christian
22 Eldwick Court
Potomac, MD 20854 / US
 [2016/26]
Representative(s)Appleyard Lees IP LLP
15 Clare Road
Halifax HX1 2HY / GB
[2016/26]
Application number, filing date14789436.422.08.2014
[2016/26]
WO2014US52209
Priority number, dateUS201361869039P22.08.2013         Original published format: US 201361869039 P
[2016/26]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015027121
Date:26.02.2015
Language:EN
[2015/08]
Type: A2 Application without search report 
No.:EP3036007
Date:29.06.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 26.02.2015 takes the place of the publication of the European patent application.
[2016/26]
Type: B1 Patent specification 
No.:EP3036007
Date:09.10.2019
Language:EN
[2019/41]
Search report(s)International search report - published on:EP14.05.2015
ClassificationIPC:A61K31/165, A61K9/00, A61K9/08, A61K9/10, A61K9/48, A61K9/107, A61P35/00
[2019/26]
CPC:
A61K9/0019 (EP,US); A61K31/165 (EP,KR,US); C07K16/2866 (US);
A61K9/0053 (EP,US); A61K9/0095 (EP,US); A61K9/08 (EP,US);
A61K9/10 (EP,US); A61K9/107 (EP,US); A61K9/48 (EP,US);
A61P35/00 (EP,KR); A61P35/02 (EP); A61P43/00 (EP);
A61K2039/505 (US); A61K38/00 (US); C07K2317/21 (US);
C07K2317/565 (US); C07K2317/76 (US) (-)
Former IPC [2019/24]A61K31/165, A61K9/00, A61K9/08, A61K9/10, A61K9/48, A61K9/107
Former IPC [2016/26]A61P35/00, A61K31/165
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/26]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KREBSBEHANDLUNG[2016/26]
English:CANCER TREATMENT[2016/26]
French:TRAITEMENT CONTRE LE CANCER[2016/26]
Entry into regional phase19.02.2016National basic fee paid 
19.02.2016Designation fee(s) paid 
19.02.2016Examination fee paid 
Examination procedure19.02.2016Examination requested  [2016/26]
28.10.2016Amendment by applicant (claims and/or description)
12.12.2018Despatch of a communication from the examining division (Time limit: M04)
08.04.2019Reply to a communication from the examining division
19.06.2019Communication of intention to grant the patent
31.07.2019Fee for grant paid
31.07.2019Fee for publishing/printing paid
31.07.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19201777.0  / EP3616754
Opposition(s)10.07.2020No opposition filed within time limit [2020/38]
Fees paidRenewal fee
29.08.2016Renewal fee patent year 03
28.08.2017Renewal fee patent year 04
27.08.2018Renewal fee patent year 05
27.08.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.08.2014
AL09.10.2019
AT09.10.2019
CY09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
MC09.10.2019
MK09.10.2019
MT09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
SI09.10.2019
SK09.10.2019
SM09.10.2019
TR09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
[2022/32]
Former [2022/27]HU22.08.2014
AL09.10.2019
AT09.10.2019
CY09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
MC09.10.2019
MT09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
SI09.10.2019
SK09.10.2019
SM09.10.2019
TR09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
Former [2021/18]AL09.10.2019
AT09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
MC09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
SI09.10.2019
SK09.10.2019
SM09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
Former [2020/51]AL09.10.2019
AT09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
SI09.10.2019
SK09.10.2019
SM09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
Former [2020/37]AL09.10.2019
AT09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
SK09.10.2019
SM09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
Former [2020/36]AL09.10.2019
AT09.10.2019
CZ09.10.2019
DK09.10.2019
EE09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
IS09.02.2020
PT10.02.2020
Former [2020/35]AL09.10.2019
AT09.10.2019
CZ09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RO09.10.2019
RS09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
PT10.02.2020
IS24.02.2020
Former [2020/32]AL09.10.2019
AT09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RS09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
PT10.02.2020
IS24.02.2020
Former [2020/25]AT09.10.2019
FI09.10.2019
HR09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
RS09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
PT10.02.2020
IS24.02.2020
Former [2020/24]AT09.10.2019
FI09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
PT10.02.2020
IS24.02.2020
Former [2020/23]AT09.10.2019
FI09.10.2019
LT09.10.2019
LV09.10.2019
NL09.10.2019
PL09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
GR10.01.2020
PT10.02.2020
Former [2020/22]FI09.10.2019
LT09.10.2019
NL09.10.2019
SE09.10.2019
BG09.01.2020
NO09.01.2020
PT10.02.2020
Former [2020/21]NL09.10.2019
NO09.01.2020
Former [2020/20]NL09.10.2019
Cited inInternational search[X]EP0196415  (BEPPU TERUHIKO [JP]) [X] 1-9,19,20,22-25 * example - *;
 [XY]WO02060430  (CORNELL RES FOUNDATION INC [US]) [X] 1-9,19-25 * example 2; claim - * [Y] 10-18;
 [XY]  - LIMEI LIU ET AL, "Trichostatin A Affects Breast Cancer Cell Viability by Modulating Fhit and Survivin Expression", BIOMEDICAL ENGINEERING AND BIOTECHNOLOGY (ICBEB), 2012 INTERNATIONAL CONFERENCE ON, IEEE, (20120528), doi:10.1109/ICBEB.2012.457, ISBN 978-1-4577-1987-5, pages 1133 - 1135, XP032207903 [X] 1-9 * page 1133 * [Y] 10-18

DOI:   http://dx.doi.org/10.1109/iCBEB.2012.457
 [XY]  - VIGUSHIN, "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo", CLINICAL CANCER RESEARCH, (20010101), XP055152712 [X] 1-9 * page 971 * [Y] 10-18
 [Y]  - JUNG-HYUN PARK ET AL, "Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, (20070913), vol. 86, no. 1, ISSN 1432-1440, pages 117 - 128, XP019576405 [Y] 10-18 * page 125 - page 127 *
 [Y]  - X WANG ET AL, "Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation", ONCOGENE, (20060522), vol. 25, no. 54, doi:10.1038/sj.onc.1209707, ISSN 0950-9232, pages 7148 - 7158, XP055152985 [Y] 10-18 * page 7156 - page 7157 *

DOI:   http://dx.doi.org/10.1038/sj.onc.1209707
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.